| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Vitreous VEGF clearance is increased after vitrectomy.
|
Invest Ophthalmol Vis Sci
|
2009
|
1.13
|
|
2
|
Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
|
J Pharmacokinet Pharmacodyn
|
2003
|
1.12
|
|
3
|
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
|
Cancer Chemother Pharmacol
|
2005
|
1.10
|
|
4
|
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine.
|
Clin Cancer Res
|
2005
|
0.99
|
|
5
|
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
|
Cancer Chemother Pharmacol
|
2007
|
0.96
|
|
6
|
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.
|
J Clin Pharmacol
|
2011
|
0.93
|
|
7
|
Nonlinear Random Effects Mixture Models: Maximum Likelihood Estimation via the EM Algorithm.
|
Comput Stat Data Anal
|
2007
|
0.93
|
|
8
|
Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.
|
Antimicrob Agents Chemother
|
2006
|
0.92
|
|
9
|
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
|
Cancer Chemother Pharmacol
|
2010
|
0.89
|
|
10
|
Population Pharmacokinetic/Pharmacodyanamic Mixture Models via Maximum a Posteriori Estimation.
|
Comput Stat Data Anal
|
2009
|
0.83
|
|
11
|
Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.
|
Am J Physiol Regul Integr Comp Physiol
|
2011
|
0.83
|
|
12
|
Pharmacokinetics of doxycycline in adults with cystic fibrosis.
|
Antimicrob Agents Chemother
|
2011
|
0.81
|
|
13
|
Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
|
Cancer Res
|
2003
|
0.81
|
|
14
|
Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning.
|
Bioinformatics
|
2010
|
0.81
|
|
15
|
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
|
Clin Pharmacokinet
|
2014
|
0.80
|
|
16
|
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
|
Pediatr Blood Cancer
|
2008
|
0.79
|
|
17
|
A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay.
|
Steroids
|
2012
|
0.79
|
|
18
|
A note on population analysis of dissolution-absorption models using the inverse Gaussian function.
|
J Clin Pharmacol
|
2008
|
0.79
|
|
19
|
Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.
|
J Pharmacokinet Pharmacodyn
|
2012
|
0.78
|
|
20
|
Editorial: Special issue on multiscale modeling and analysis in computational biology and medicine--part-1.
|
IEEE Trans Biomed Eng
|
2011
|
0.78
|
|
21
|
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
|
J Pharmacokinet Pharmacodyn
|
2014
|
0.76
|
|
22
|
Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice.
|
Diabetologia
|
2013
|
0.76
|
|
23
|
The emerging scientific discipline of pharmacometrics.
|
J Clin Pharmacol
|
2010
|
0.75
|
|
24
|
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
|
AAPS J
|
2013
|
0.75
|
|
25
|
Editorial: TBME Letters special issue on multiscale modeling and analysis in computational biology and medicine--part-2.
|
IEEE Trans Biomed Eng
|
2011
|
0.75
|
|
26
|
Analysis of intravenous glucose tolerance test data using parametric and nonparametric modeling: application to a population at risk for diabetes.
|
J Diabetes Sci Technol
|
2013
|
0.75
|
|
27
|
Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.
|
J Antimicrob Chemother
|
2017
|
0.75
|
|
28
|
ACoP: the tools, carpenters, and architects building the discipline of pharmacometrics.
|
J Clin Pharmacol
|
2010
|
0.75
|
|
29
|
Defining the future of pharmacometrics: the American Society of Pharmacometrics.
|
J Clin Pharmacol
|
2010
|
0.75
|